Specifically, we identified CCRL2, LGALS9, and PLCB2 as key genes associated with abnormal ESS and AS and initially explored the roles of these genes in endothelial dysfunction and AS, thus highlighting the possibility of new preventive and therapeutic strategies for AS by targeting these genes. This evidence concerns the gene PLCB2 and endothelial dysfunction.